Cape Investment Advisory’s Ionis Pharmaceuticals IONS Stock Holding History

Cape Investment Advisory’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.11K	Buy	+14	New	+$1.05K	﹤0.01%	1319
2026 Q1	–	Sell	-6	Closed	-$475	–	685
2025 Q4	$475	Buy	+6	New	+$452	﹤0.01%	1248
2024 Q1	–	Sell	-2	Closed	-$101	–	1046
2023 Q4	$101	Sell	2 -4	-67%	-$192	﹤0.01%	1112
2023 Q3	$272	Hold	6	–	–	﹤0.01%	887
2023 Q2	$246	Sell	6 -7	-54%	-$269	﹤0.01%	879
2023 Q1	$465	Buy	+13	New	+$488	﹤0.01%	911

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Cape Investment Advisory's IONS Position: Q2 2026 in Review

Cape Investment Advisory opened a new position in Ionis Pharmaceuticals (IONS) in Q2 2026: 14 shares worth $1.11K. The stake represents ﹤0.01% of the portfolio and ranks #1319 among its holdings. This is a return to the name: Cape Investment Advisory previously reported a position in IONS as recently as Q4 2025.

Cape Investment Advisory first reported a position in IONS in Q1 2023 and has held it in 6 quarters since. 515 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

Cape Investment Advisory held 14 shares of Ionis Pharmaceuticals worth $1.11K as of Q2 2026.
Ionis Pharmaceuticals was a new Cape Investment Advisory position in Q2 2026.
Ionis Pharmaceuticals made up ﹤0.01% of Cape Investment Advisory's portfolio in Q2 2026, its #1319 holding.
Cape Investment Advisory first reported a position in Ionis Pharmaceuticals in Q1 2023 and has held it in 6 quarters since.
515 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Cape Investment Advisory's 13F filing for Q2 2026, filed 23 Jul 2026.